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Abstract
We previously demonstrated prolonged, profound CD4+ T-
lymphopenia in rheumatoid arthritis (RA) patients following
lymphocyte-depleting therapy. Poor reconstitution could result
either from reduced de novo T-cell production through the
thymus or from poor peripheral expansion of residual T-cells.
Interleukin-7 (IL-7) is known to stimulate the thymus to produce
new T-cells and to allow circulating mature T-cells to expand,
thereby playing a critical role in T-cell homeostasis. In the
present study we demonstrated reduced levels of circulating IL-
7 in a cross-section of RA patients. IL-7 production by bone
marrow stromal cell cultures was also compromised in RA. To
investigate whether such an IL-7 deficiency could account for
the prolonged lymphopenia observed in RA following
therapeutic lymphodepletion, we compared RA patients and
patients with solid cancers treated with high-dose
chemotherapy and autologous progenitor cell rescue.
Chemotherapy rendered all patients similarly lymphopenic, but
this was sustained in RA patients at 12 months, as compared
with the reconstitution that occurred in cancer patients by 3–4
months. Both cohorts produced naïve T-cells containing T-cell
receptor excision circles. The main distinguishing feature
between the groups was a failure to expand peripheral T-cells in
RA, particularly memory cells during the first 3 months after
treatment. Most importantly, there was no increase in serum IL-
7 levels in RA, as compared with a fourfold rise in non-RA
control individuals at the time of lymphopenia. Our data
therefore suggest that RA patients are relatively IL-7 deficient
and that this deficiency is likely to be an important contributing
factor to poor early T-cell reconstitution in RA following
therapeutic lymphodepletion. Furthermore, in RA patients with
stable, well controlled disease, IL-7 levels were positively
correlated with the T-cell receptor excision circle content of
CD4+ T-cells, demonstrating a direct effect of IL-7 on thymic
activity in this cohort.
Keywords: immune reconstitution, interleukin-7, T-cell differentiation, therapeutic lymphodepletion
Introduction
Peripheral blood T-cell lymphopenia is long-lasting in
patients with rheumatoid arthritis (RA) receiving lymphode-
pleting therapies, such as monoclonal antibodies [1-3] orR80
ACR = American College of Rheumatology; CRP = C-reactive protein; ELISA = enzyme-linked immunosorbent assay; IL = interleukin; OA = osteoar-
thritis; PBMC = peripheral blood mononuclear cell; RA = rheumatoid arthritis; TNF = tumour necrosis factor; TREC = T-cell receptor excision circle.
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R81high-dose cyclophosphamide with autologous stem cell
rescue (autologous stem cell transplantation) [4,5]. It has
now been extensively documented in a number of systems
that IL-7 drives the survival and proliferation of human T-
cells after lymphodepletion (for review [6]). In particular,
high circulating levels of this cytokine have been docu-
mented in patients rendered lymphopenic either by lym-
phocytotoxic treatment [7] or by HIV infection [8-10]. IL-7
produced in response to lymphopenia stimulates prolifera-
tion of both naïve and memory human T-cells [7], but also
has a direct stimulating effect on thymic activity [11]. IL-7
plays many other roles such as the induction/enhancement
of a T-helper-1 immune response [12,13], maturation of
monocytes into dendritic cells, recruitment and expansion
of T-cell clones [14-16], and induction of natural killer cell
lytic activity [17-19]. These make IL-7 a master modulator
of T-cell-mediated immune responses, particularly in
tumour surveillance and eradication, in addition to its role
as master regulator of peripheral T-cell homeostasis [8]
Specific abnormalities within the naïve T-cell compartment
in RA, such as repertoire contraction and shortened telom-
eres, have suggested a possible defect in generating and/
or maintaining naive T-cells [20-23]. Furthermore, we
recently showed [24] that RA patients possessed fewer
naïve CD4+ T-cells than did healthy control individuals and
that a smaller proportion of these cells contained a T-cell
receptor excision circle (TREC). Circulating C-reactive pro-
tein (CRP) levels correlated inversely with the TREC con-
tent of naïve CD4+ T-cells, suggesting that inflammation
was driving naïve CD4+ T-cell proliferation and differentia-
tion, leading to dilution of TREC-containing cells. We could
not, however, exclude an additional intrinsic defect in
thymic T-cell production in RA patients [24].
In recent studies we reported persistent and profound
CD4+ T-cell lymphopenia in RA patients as long as 7 years
after a single course of CAMPATH-1H monoclonal anti-
body treatment [25] and up to 36 months after autologous
stem cell transplantation [26]. RA patients usually reconsti-
tute their B and natural killer cells rapidly, whereas CD8+ T-
cell reconstitution takes longer and full recovery of CD4+ T
cells may never occur. This is in contrast to patients under-
going bone marrow or stem cell transplantation for haema-
tological malignancy or solid tumours, in whom both T-cell
compartments reconstitute within 1 year of follow up [27-
29]. Poor reconstitution after lymphodepleting therapy is
likely to result either from reduced de novo T-cell produc-
tion from the thymus or from poor peripheral expansion of
naïve and memory cells, both of which processes are driven
by IL-7.
Here we report on a deficit in circulating levels of IL-7 in a
cross-section of RA patients. This is associated with a
reduced production of IL-7 in bone marrow derived stromal
cell cultures, and may contribute to the defective CD4+ T-
cell reconstitution that occurs following therapeutic lym-
phodepletion, primarily at the level of mature T-cell expan-
sion in the periphery. Furthermore, we show that TREC
levels correlate with circulating levels of IL-7 in patients in
whom inflammation is controlled.
Methods
Patient cohorts
Ethical approval for the project was obtained from the
Leeds Teaching Hospitals National Health Service Trust
Ethics Committee, and informed consent was obtained
from each participant. Healthy control individuals were
recruited from among local blood donors (n = 34). RA (n =
28) and osteoarthritis (OA; n = 12) patients were recruited
through routine clinics at the Leeds General Infirmary
(Table 1). They included patients with early, drug naïve (n =
7) and long-lasting, refractory (n = 21) RA (CRP range 5–
155 mg/l) and patients with established, long-lasting OA (n
= 12; CRP below detection range).
For the reconstitution studies we analyzed three RA patient
cohorts (n = 31) and a cohort of non-RA patients with solid
tumours (n = 7; Table 2). Each RA patient received high-
dose cytotoxic therapy followed by autologous haemato-
logical transplants [26,30,31]. Each had disease that had
proved resistant to multiple conventional antirheumatic
drugs. Cohort 1 received an unmanipulated graft; cohort 2
received a graft that had undergone selection for CD34+
cells; and cohort 3 received a graft that had been CD34+
cell selected and T-cell depleted. The clinical progress of
these patients was previously described elsewhere
[26,30,31]. Control patients (Table 2) included five individ-
uals with lung carcinoma, one with breast carcinoma and
one with melanoma. They received unmanipulated autolo-
gous grafts following high-dose chemotherapy, as previ-
ously documented [32]. For the IL-7 longitudinal studies,
we analyzed four lymphoma and three sarcoma patients. All
received intensive chemotherapy followed by reinfusion of
unmanipulated autologous stem cells (Table 2). In addition,
we studied three patients with systemic vasculitis who
received the lymphocytotoxic monoclonal antibody CAM-
PATH 1H [33].
For our work on RA patients in clinical remission (Table 1),
we recruited consecutive patients (n = 36) attending the
rheumatology outpatient clinics with stable RA. They pos-
sessed no clinically significant synovitis and were deemed
to be in 'remission' by the assessing consultant rheumatol-
ogist. Patients satisfied all of the following inclusion criteria:
previous certified diagnosis of RA; over 18 years of age;
disease duration of at least 12 months before remission; no
disease flare within preceding 6 months; stable treatment
within preceding 6 months; nil or minimal clinical evidence
of active inflammatory disease and CRP below 15 mg/l
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change treatment. We further refined this cohort by sepa-
rating patients into those who satisfied the American Col-
lege of Rheumatology (ACR) remission criteria and those
who did not (Table 3).
Cytokine measurements
IL-7, transforming growth factor-β1, IL-6, tumour necrosis
factor (TNF)-α and oncostatin M levels in sera and in tissue
culture supernatants were measured using enzyme-linked
immunosorbent assay (ELISA; R&D, Abingdon, UK), in
accordance with the manufacturer's instructions. The sen-
sitivities of the assay were <0.1 pg/ml for IL-7, 0.2 pg/ml for
IL-6, 0.5 pg/ml for TNF-α, and 20 pg/ml for oncostatin M.
T-cell subset separation
Peripheral blood mononuclear cells (PBMCs) were recov-
ered as described previously [24], and CD4+ and CD8+ T
cells were separated by negative selection (Metachem,
Meylan, France). Purified CD4+ and CD8+ T cells (>92%
pure for CD4+ and 89% pure for CD8+ T cells) were
stained for CD45RB (FITC; Dako, Ely, UK), CD45RA (PE;
Serotec, Oxford, UK), CD45RO (PE-CY5; Serotec) and
CD62L (ECD Coulter, High Wycombe, UK) using conven-
tional methods. Naïve T-cells were further sorted according
to their CD45RBbright, CD45RA+ and CD62L+ phenotype,
using a FACS-Vantage cell sorter (Becton Dickinson,
Oxford, UK). Memory cells and other subsets were identi-
fied based on their expression of CD45RBbright/dull,
CD45RA±, CD45RObright/dull, and CD62L± [24].
Real-time polymerase chain reaction quantification of T-
cell receptor excision circles
DNA was extracted from the different lymphocyte popula-
tions using standard proteinase K digestion followed by a
phenol/chloroform extraction, either from total CD4+ and
CD8+ populations after magnetic separation or from naïve
cells after further cell sorting. TRECs were quantified using
a real-time polymerase chain reaction based assay, as
described previously [24]. Briefly, TREC primers were F (d-
CAC CTC TGG GCT ACG TGC TAG) and R (d-GAA
CAC ATG CTG AGG TTT AAA GAG AAT); and glyceral-
dehyde-3-phosphate dehydrogenase primers were F (D-
AAC AGC GAC ACC CAT CCT C) and R (d-CAT ACC
AGG AAA TGA GCT TGA CAA). This analysis provided a
final value that represented TREC DNA as a proportion of
Table 1
Rheumatoid arthritis patients with active or stable, well controlled disease and control individuals
Parameter Controls Active RA OA RA in remission
n 34 28 12 36
Age (mean ± standard deviation [range]; 
years)
48 ± 16 (24–62) 51 ± 17 (20–83) 60 ± 9 (49–73) 48 ± 11 (25–67)
Sex (male/female) 6/17 9/28 3/9 7/29
Disease duration (mean ± standard 
deviation [range]; years)
NA 5.1 ± 7.5 (0.1–37) NA 9.3 ± 6.8 (2–28)
Remission duration (mean ± standard 
error [range]; months)
NA NA NA 29 ± 29 (6–144)
CRP (mean ± standard deviation [range]; 
mg/l), below /above detectiona
NA 55 ± 52 (5–164), 0/28 NA 3.5 ± 5.2 (0–12), 23/13
aC-reactive protein (CRP) values <5 mg/l are considered below the detection range. CRP values <10 mg/l are considered normal among the 
local population. NA, not applicable; OA, osteoarthritis; RA, rheumatoid arthritis.
Table 2
Patients receiving depleting therapies
Patients n Agea range (median; years) Sex (male/female) Graft manipulation
RA cohort 1 9 32–61 (42) 2/7 Unmanipulated
RA cohort 2 16 43–55 (47) 4/12 CD34 selection
RA cohort 3 6 24–61 (39) 3/3 CD34 selection, T-cell depletion
Solid tumours 7 39–64 (44) 2/5 Unmanipulated
Lymphoma/sarcoma 7 22–64 (46) 5/2 Unmanipulated
Systemic vasculitis (depleting 
antibody therapy)
3 43–61 (52) 2/1 Not applicable
aAge at time of transplantation. RA, rheumatoid arthritis.
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is equivalent to the percentage of cells containing a TREC.
Following the release of the entire T-cell receptor locus
sequence late in 2002, we validated our assay utilizing an
alternative set of TREC primers designed to minimize back-
ground signal when using PBMC DNA.
Proliferation assays
PBMCs were separated as above from 5 ml blood from RA
patients and healthy control individuals. An aliquot of
PBMCs was stained with a combination of CD127 (FITC;
Serotec), CD19 (PE; Serotec) and CD4 or CD8 (PE-CY5;
Serotec) to quantify IL-7 receptor expression on different
cell types by flow cytometry. Cells were resuspended in
RPMI 1640 supplemented with penicillin and streptomycin,
glutamine and 10% human AB+ serum (Sigma, Aldwich,
UK) and proliferation was assessed in response to PHA
(10 µg/ml, Sigma), IL-2 (20 units/ml; Sigma), IL-7 (1–100
ng/ml; Sigma) or anti-CD3 antibody (OKT3; 1 µg/ml) with
or without anti-CD28 antibody (YTH913.12; 5 µg/ml) co-
coated on plastic Proliferation was quantified by incorpora-
tion of 3H-thymidine (1 µCi/well) after 5 days of culture.
Long-term bone marrow cultures
Bone marrow mononuclear cells were obtained from pos-
terior iliac crest aspirates from RA patients and healthy con-
trol individuals after informed consent had been obtained
(with local research ethics committee approval), following
centrifugation on Lymphoprep (Nycomed Pharma AS,
Oslo, Norway), as previously described [34,35]. Aspirates
from RA patients were repeated after 6–8 months of ther-
apy with infliximab (Remicade; Schering Plough, Kenil-
worth, NJ, USA). Long-term bone marrow cultures from 107
bone marrow mononuclear cells were grown, in accord-
ance with standard techniques [34,35]. By allowing the for-
mation of an adherent layer consisting mainly of
macrophages and cells of mesenchymal origin, this culture
system has been considered appropriate for evaluating the
regulatory role played by the bone marrow microenviron-
ment in haematopoiesis [36]. At weekly intervals, cultures
were fed by demi-depopulation. The adherent layer was
usually confluent after 3–4 weeks, and at that time point
cell-free supernatants were harvested and stored at -70°C
for cytokine quantification.
Statistical methods
Nonparametric tests were used throughout. The Mann–
Whitney U-test for two independent samples was used to
compare healthy control individuals with RA patients. The
Spearman rank correlation coefficient was used to deter-
mine correlations between two variables. A Wilcoxon sign
rank test was used to compare pretherapy and post-ther-
apy outcomes.
Results
Basal interleukin-7 production is reduced in rheumatoid 
arthritis
We measured serum levels of IL-7 in a cross-section of
active RA patients (n = 28), healthy control individuals (n =
34) and OA patients (n = 12). There was no correlation
between serum levels of IL-7 and age in healthy control
individuals [37,38], and sex did not make any difference.
Circulating IL-7 levels (Fig. 1a) were significantly lower in
RA patients than in healthy control individuals (P <
0.00001). In RA there was no association between levels
of circulating IL-7 and disease duration, inflammation as
measured by CRP (Fig. 1b; nonsignificant correlation [R =
0.201, P = 0.161]), presence of a shared epitope (n = 17),
or antirheumatic therapy (nonsteroidal anti-inflammatory
drugs, methotrexate, or steroids). OA patients exhibited
slightly lower IL-7 levels than did control individuals (P =
0.035) but they had significantly higher IL-7 levels than did
RA patients (P < 0.00001). After Bonferroni correction
there was no longer a significant difference between con-
trol individuals and OA patients, but other results remained
unaffected. Regression analysis did not reveal any further
trends.
Table 3
Patients in clinical remission satisfying or not satisfying the American College of Rheumatology criteria for remission
Parameter Remission by ACR criteriaa Nonremission by ACR criteriaa
N 17 19
Age (mean ± standard deviation [range]; years) 48 ± 11 (28–67) 54 ± 11 (39–67)
Sex (male/female) 3/14 4/15
Disease duration (mean ± standard deviation [range]; years) 9.8 ± 6.6 (3–25) 9.7 ± 6.3 (2–28)
Remission duration (mean ± standard deviation [range]; months) 26 ± 16 (6–60) 30 ± 36 (6–144)
CRP (mean ± standard deviation [range]; mg/l), below/above 
detectionb
3.0 ± 3.8 (0–10), 10/7 4.0 ± 5.2 (0–12), 13/6
aAmerican College of Rheumatology (ACR) remission criteria : less than 15 min morning stiffness; no fatigue; no joint pain; no joint tenderness or 
pain on motion; no swelling of soft tissue in joint or tendon sheaths; and <30 mm/h erythrocyte sedimentation rate. bC-reactive protein (CRP) 
values <5 mg/l are considered below the detection range. CRP values <10 mg/l are considered normal among the local population.
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stromal cells in the bone marrow, dendritic cells and epithe-
lial cells in the thymus, skin and gut [6]. We compared the
ability of bone marrow stromal cells, derived from RA
patients (n = 9) and healthy control individuals (n = 15), to
produce IL-7 spontaneously in long-term cultures (Fig. 1c).
The production of IL-7 was significantly lower in RA
patients than in control individuals (P = 0.001).
Furthermore, production did not consistently change after
clinical remission induced by therapeutic TNF-α blockade
(n = 8; P = 0.725). We also examined the PBMC response
to IL-7 in RA patients and healthy control individuals.
Whereas RA PBMCs responded suboptimally to IL-2,
mitogen (PHA) or antigen (anti-CD3/CD28), as previously
documented [39], their response to IL-7 was similar to that
in control individuals (Fig. 1d). Importantly, in a cross-sec-
tional comparison of 10 RA patients and 10 healthy control
individuals, we could not find a significant difference in the
number of cells expressing the IL-7 receptor (CD127) or in
its level of expression (data not shown). Altogether, these
findings suggest a deficit in circulating levels of IL-7 in RA,
possibly due to an inability to produce IL-7, at least in stro-
mal cells of bone marrow origin.
Figure 1
IL-7 deficiency in rheumatoid arthritis (RA). (a) IL-7 levels were measured in serum from 34 healthy control individuals (median age 46 years), 28 
patients with RA (seven with recent onset RA before institution of therapy and 21 with established, refractory RA; median age 55 years) and 12 
patients with established osteoarthritis (OA; median age 56 years). Control individuals had significantly higher levels of circulating IL-7 than did RA 
patients (P < 0.00001). OA patients tended to have lower IL-7 levels than healthy control individuals (P = 0.035) but higher than RA patients (P < 
0.00001). (b) IL-7 levels were plotted against C-reactive protein (CRP) values for 28 patients with active RA, but no relationship could be identified 
(R = 0.201, P = 0.161). (c) Bone marrow was obtained by aspiration from the iliac crest from healthy control individuals (n = 15) and from RA 
patients (n = 8) before and after therapeutic tumour necrosis factor (TNF)-α blockade. Long-term bone marrow stromal cell cultures were estab-
lished, and spontaneous IL-7 release was measured. Control bone marrow stromal cells released significantly more IL-7 than did RA marrow (P = 
0.001). There was no consistent effect of anti-TNF-α therapy on IL-7 expression (paired pre-post treatment test). (d) Peripheral blood mononuclear 
cells from healthy control individuals (n = 3) and RA patients (n = 3) were cultured in the presence of PHA (10 µg/ml), IL2 (20 U/ml), anti-CD3 (1 
µg/ml) plus anti-CD28 (5 µg/ml), or titrated doses of IL-7 (1–100 ng/ml), for 5 days. Proliferation was assayed by 3H-thymidine incorporation. RA 
and healthy cells responded similarly to IL-7, but RA cells were hyporesponsive to other stimuli.
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R85Defective T-cell expansion in rheumatoid arthritis
Patients receiving lymphocytotoxic therapy for conditions
other than RA reconstitute more rapidly and completely
than do RA patients. We previously studied three cohorts
of RA patients who had received high-dose chemotherapy
followed by stem cell reinfusion (Table 2). As previously
reported [26,30,31], CD4+ counts fell after treatment and
subsequently remained low in all cohorts, with no signifi-
cant differences due to graft manipulation (data not
shown). In contrast, CD8+ T-cell counts initially rose before
rapidly returning to basal levels.
In the present study we compared T-cell reconstitution in
12 RA patients (six from each of cohorts 2 and 3) and
seven patients with solid tumours (Fig. 2 and Table 2). To
avoid potential confounding effects of immunosuppressive
drugs, RA patients were removed from the analysis if it sub-
sequently became necessary to reinstitute antirheumatic
therapies at times when disease activity resumed. The fig-
ure therefore represents 12 RA patients pretreatment and
seven at 9 months.
The chemotherapy regimens differed between RA and non-
RA patients, but the nadir lymphocyte counts were similar.
Figure 2 illustrates the composition of the peripheral T-cell
pool at baseline and at various times after treatment. The
individual subsets were defined according to the lym-
phocyte differentiation pathway suggested by our previous
work [24]. The most naïve cells are represented in grey at
the top of each bar chart. These cells progress to conven-
Figure 2
Poor T-cell expansion in rheumatoid arthritis (RA) patientsi . Phenotyping of isolated CD4+ and CD8+ T-cell populations was performed using the cell 
surface markers CD45RB, CD45RA, CD45RO and CD62L. Differentiation subsets were defined as naïve cells (grey bars: CD45RBbright, 
CD45RA+, CD45RO-, CD62L+), conventional memory cells and their precursors (striped bars: CD45RBbright/dull, CD45RA-, CD45RO+, CD62L-) 
and post-naïve intermediates (white bars: CD45RBbright/dull, CD45RA-, CD45RO-/dull, CD62L+), as described previously [24]. Presumed 'central' 
memory cells (black bars) are CD45RBdull, CD45RA+, CD45RO+ and CD62L+. Total T-cell numbers are indicated by the height of the bars. Lines 
across the graphs indicate the lower limits of the normal range for CD4+ and CD8+ T-cell counts. Cancer patients (n = 7 solid tumours [Table 2]) 
reconstitute CD4+ T cells largely by expansion of intermediate and memory subsets. This is not seen in RA patients (n = 12 at baseline and 1 month, 
n = 7 at 9 months; six patients from each of cohorts 2 and 3 [Table 2]). A similar expansion accounts for the 'overshoot' above baseline in CD8+ T-
cells in cancer patients, whereas only a minimal transient expansion of memory CD8+ T-cells is observed in RA.
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R86tional memory cells and their precursors (striped bars) via
post-naïve cells (white bars). Presumed 'central' memory
cells are presented in black. Notably, at baseline RA
patients possessed no CD4+ and CD8+ central memory
cells in peripheral blood, as reported previously [24]. After
chemotherapy there was simultaneous accumulation of all
subsets in cancer patients, resulting in rapid restitution of
CD4+ T-cell counts within 3 months. The same was true of
the CD8+ subsets except that there was an 'overshoot' of
memory CD8+ T-cells. In contrast, there was no early
expansion of any T-cell subset in RA, although some long-
term restoration of naïve CD4+ subsets was observed.
Naïve CD8+ T-cells also accumulated slowly, and there was
a brief expansion of CD8+ memory cells. These marked dif-
ferences between RA and cancer patients demonstrate
that a limited early peripheral expansion after treatment may
account, in part, for the lack of T-cell reconstitution in RA.
Although graft manipulation differed between cancer
patients (un-manipulated) and RA (CD34 selected ± T-cell
depletion) as mentioned above, we found that graft manip-
ulation did not affect the rate of reconstitution in RA
patients (data not shown). Other factors that differ between
the RA and control group reflect the underlying disease.
For example, RA patients may have been exposed to low-
dose corticosteroid therapy as part of their prior treatment.
It is not possible to exclude an effect of such a factor on our
data.
Delayed thymic activity in rheumatoid arthritis
In order to compare thymic activity after lymphodepletion,
we measured TRECs longitudinally in CD4+ T-cells in the
same RA and cancer patient cohorts. As a molecular
marker of T-cell receptor rearrangement, TRECs provide a
surrogate measure of recent thymic activity [40,41]. We
measured TREC content in total CD4+-T cells as well as in
naïve CD4+-T cells in isolation. Patterns of TREC variation
were consistent between the seven cancer patients.
TRECs rapidly accumulated after treatment but returned to
baseline by 3 months (Fig. 3; open diamonds). Our data in
cancer are therefore consistent with an early surge in
thymic activity, followed by a slow return to baseline at a
time when the T-cell counts have returned to baseline lev-
els. Variation in the TREC content of naïve cells also
followed that pattern. The reduction in TREC content of an
individual subset such as naïve cells is better explained by
proliferation within that subset [24,42,43], therefore sug-
gesting that naïve T-cells underwent peripheral expansion,
resulting in TREC dilution in CD4+ cells (open diamonds).
Similar results were observed for CD8+ T cells (data not
shown).
The early thymic response to lymphopenia did not occur in
the 12 RA patients. In contrast, the TREC content of total
CD4+ T-cells climbed gradually for several months after
treatment (Fig. 3; closed diamonds). The TREC measure-
ments in naïve cells also did not return to baseline, how-
ever, suggesting a lack of proliferation of CD4+ naïve cells.
Therefore, a delay in achieving good release of newly devel-
oped T-cells also appeared to contribute to slow T-cell
reconstitution in RA after high-dose chemotherapy. Similar
results were observed for CD8+ T-cells (data not shown).
Lymphopenia-induced interleukin-7 production is 
defective in rheumatoid arthritis
Figures 2 and 3 suggest that the development and expan-
sion of CD4+ T-cells were compromised in lymphopenic
RA patients. Both the development and expansion of T
cells have been extensively documented in relation to IL-7
(for review [6]). The relative deficiency in circulating IL-7
levels in RA patients identified in Fig. 1 therefore suggests
a significant role for IL-7 in impaired T-cell reconstitution
following high-dose chemotherapy. We measured serum
levels of IL-7 longitudinally in four RA patients after lym-
phodepleting therapy (cohort 3, without relapse within 12
months) and seven non-RA patients (Table 2). Figure 4
clearly demonstrates a four- to fivefold rise and subsequent
Figure 3
Thymic reserve in lymphopenic cancer and rheumatoid arthritis (RA) patients
patients. The proportion of T cells containing a T-cell receptor excision 
circle (TREC) was measured longitudinally in cancer (n = 7 solid 
tumours [Table 2]) and RA (n = 12 at baseline and 1 month, six patients 
from both of cohorts 2 and 3 [Table 2]; and n = 7 at 9 months, three 
from cohort 2 and four from cohort 3) patients' pure CD4+ T-cells and 
following cell sorting of naïve cells. In cancer patients TRECs rapidly 
rose within 1 month and then slowly returned to pretreatment levels by 
8 months. In RA patients there was a slow but sustained rise in TRECs 
over that time, achieving similar peak levels to cancer patients by 9 
months.
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R87decrease in IL-7 levels, coincident with short-term lympho-
penia in non-RA patients (triangles). In marked contrast, IL-
7 levels did not change significantly in four RA patients over
12 months of follow up (squares).
Interleukin-7 levels correlated with thymic activity in 
patients with well controlled rheumatoid arthritis
In RA patients whose disease was controlled by in vivo
TNF blockade, spontaneous release of IL-7 from bone mar-
row derived stromal cell cultures was variable, remaining
reduced in some patients but returning to normal in others
(Fig. 1). We therefore decided to investigate IL-7 levels in
patients with well controlled disease and minimal levels of
disease activity for at least 6 months before recruitment (n
= 36; Table 1). Levels of IL-7 were heterogeneous and
ranged from 2.47 to 16.25 pg/ml. No clinical parameter
was significantly correlated with IL-7 levels (disease dura-
tion, remission duration, previous or current therapy, rheu-
matoid factor).
We measured TREC in total CD4+ T-cells in these patients
in clinical remission in relation to age. The results were also
heterogeneous (Fig. 5a; all triangles). Comparing these
values with our previous results in healthy control individu-
als (small circles [24]), there appeared to be two distinct
patient groups. One of these groups had a CD4+ T-cell
TREC content similar to or higher than that in age-matched
healthy control individuals, and the other group exhibited
lower TREC content. We used the median TREC content
to distinguish two groups. Open and closed triangles relate
to group 1 (above the median TREC value) and group 2
(below the median TREC value), respectively. The relation-
ship between TREC content and age was present in group
1 (thick line; R = -0.738, P = 0.001) but not in group 2. No
clinical parameter was able to predict TREC content (dis-
ease duration, remission duration, previous or current ther-
apy, rheumatoid factor).
Figure 4
Lower circulating levels of IL-7 in rheumatoid arthritis (RA). IL-7 levels 
were measured in serum samples taken longitudinally from RA patients 
(n = 6 at baseline and 1 month, n = 4 subsequently; patients without 
relapse all from cohort 3) or patients with lymphoma, cancer or sys-
temic vasculitis (n = 4 up to 3 month, n = 2 afterward), all of whom 
were lymphopenic for up to 3 months after lymphodepleting therapies. 
IL-7 circulating levels remained low in RA patients, compared with a 
substantial rise in the mixed cohort of non-RA patients.
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Figure 5
Circulating IL-7 levels are directly correlated with the TREC content of D4+ T-cells in rheum toi  arthritis (RA) patients in clinical remission
CD4+ T-cells in rheumatoid arthritis (RA) patients in clinical remission. 
(a) The T-cell receptor excision circle (TREC) content of total CD4+ T-
cells, measured in patients in clinical remission (n = 36, all triangles 
[Table 1]), is heterogeneous, ranging from values observed in healthy 
control individuals to values in active RA patients. Using the age rela-
tionship to TREC content in healthy control individuals (black circles 
and thin line, correlation coefficient R = -0.816, P < 0.00001; previ-
ously reported [24]), two groups of patients can be differentiated: 
group 1 exhibits TREC content similar to or greater than that in age-
matched healthy control individuals; and group 2 exhibits lower TREC 
content. We used the median value for TREC content to separate 
patients into two groups. We refer to these two groups as group 1 (G1; 
above median value, indicated by black triangles) and group 2 (G2; 
below median value, indicated by open triangles). The age relationship 
to TREC content is recovered only in group 1 (thick line; correlation 
coefficient R = -0.738, P = 0.001; for group 2 R = 0.341, P = 0.174). 
(b) Circulating IL-7 levels are directly correlated with TREC content of 
CD4+ T-cells in 36 patients in clinical remission (R = 0.777, P < 
0.00001). In addition, patients satisfying the American College of 
Rheumatology (ACR) criteria for remission are indicated by open dia-
monds and patients not satisfying the ACR criteria by closed diamonds 
(Table 3). These two groups are undistinguishable.
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R88We reanalyzed the IL-7 data with respect to this dichotomy
in TREC levels, and there was a significant difference in cir-
culating levels of IL-7 between these two groups (group 1,
n = 17: IL-7 12.71 ± 2.76 pg/ml, range 9.57–16.25 pg/ml;
group 2, n = 19: IL-7 6.50 ± 1.88 pg/ml, range 2.47–9.30
pg/ml; P < 0.00001). Furthermore, there was a positive
correlation between the levels of circulating IL-7 and the
TREC content of total CD4+ T cells (Fig. 5b; n = 36, all dia-
monds; R = 0.777, P < 0.00001). No similar relationship
was observed in healthy control individuals (n = 12; R =
0.219, P = 0.595).
We subsequently reanalyzed the data according to the
ACR criteria for clinical remission [44,45]. Patients fulfilling
or not fulfilling the ACR criteria (Table 3) are shown as open
and black diamonds, respectively, in Fig. 5b. The two pop-
ulations were undistinguishable in terms of TREC content
(P = 0.807). There was no difference in their circulating
levels of IL-7 (ACR positive: 9.07 ± 3.33 pg/ml, range 4.9–
15.23 pg/ml; ACR negative: 9.31 ± 4.01 pg/ml, range
2.47–16.25 pg/ml; P = 0.838). Furthermore, the correla-
tion between IL-7 and TREC content was maintained in
both groups (ACR positive, n = 17: R = 0.680, P = 0.005;
ACR negative, n = 19: R = 0.779, P = 0.001). These data
suggest that, removing any influence of systemic inflamma-
tion, RA patients form two groups that are characterized by
normal or low levels of thymic activity and IL-7. It is not
possible to predict from these data whether these abnor-
malities are primary or, indeed, whether they have patho-
genic significance. However, they may be important in the
context of reconstitution capacity after lymphodepleting
therapies.
Discussion
We previously demonstrated that RA patients failed to
reconstitute their peripheral T-cell pool even several years
after lymphodepleting therapy [25,26,30,31]. The aim of
the present work was to identify possible factors underlying
this observation. IL-7 drives the expansion of human T-cells
[8,46,47], and moreover it is an important thymic stimulant
[11]. We identified a deficit in circulating levels of IL-7 in a
cross-section of patients with active RA (Fig. 1). It was
therefore possible that a similar deficit in IL-7 was a critical
factor in the suboptimal response to lymphopenia in RA
patients. Our data suggest that the RA thymus has a similar
reserve to the thymus of disease control individuals (Fig. 3;
similar peak levels at 9 months in RA as at 1 month in can-
cer), although it exhibits a more sluggish response to
lymphopenia. However, both naïve and memory RA T-cells
expand poorly in response to lymphopenia (Fig. 2), and this
appears to be the major factor limiting reconstitution. We
have also demonstrated low levels of lymphopenia-induced
circulating IL-7 in RA patients (Fig. 4), and low basal IL-7
production from stromal cells originating from the bone
marrow (Fig. 1). Finally, we showed a direct correlation
between circulating levels of IL-7 and thymic capacity to
produce new T-cells in RA patients with clinically undetec-
table disease activity (Fig. 5).
To date, IL-7 is not a cytokine that has been associated with
RA. However, there are conflicting results regarding its
expression in RA patients. In one study [48] IL-7 was
present at high levels in the serum of adult RA patients, and
it correlated with CRP. In contrast, in children with systemic
juvenile RA, plasma levels of IL-7 were unrelated to disease
activity (joint counts and circulating IL-6) and undetectable
in synovial fluids [49]. In another study, IL-7 was elevated in
RA synovial fluid but not in OA [50] and its production was
associated with stromal cells in the synovium [51]. Circulat-
ing levels of IL-7 in healthy control individuals are also very
heterogeneous between publications (ranging from 0.1 to
30 pg/ml), possibly because of the use of different ELISA
systems (commercial IL-7 ELISA kits using monoclonal or
polyclonal antibodies, in-house sandwich ELISA using pol-
yclonal rabbit antisera). In our study we found that IL-7 lev-
els were highly dependent on the condition of serum
collection (in particular, the type of Vacutainer [Greiner Bio-
one, Knemsmuster, Austria; standard NHS supply]) and we
standardized our collection protocol (blood taken into plain
glass tubes, clotting time of 2 hours at room temperature,
centrifugation at 1000 g for 10 min, storage at -20°C). In
addition, in a recent report from Fry and Mackall [8], circu-
lating levels of IL-7 in CD4+ T-cell depleted and repleted
HIV patients were in keeping with our findings (<30 pg/ml
and 10–20 pg/ml, respectively).
Peripheral T-cell expansion differed greatly between our
patient groups, as shown in Fig. 2. This was particularly
obvious for memory cells and their precursors, and
appeared sufficient to account for the reconstitution defect
in RA. However, lack of TREC dilution in naïve T-cells (Fig.
3) also suggested an absence of expansion within that sub-
set in RA. IL-7 deficiency may again be relevant. IL-7 is pro-
duced in response to lymphopenia [7] and stimulates
proliferation of both naïve and memory human T-cells.
Although serum was not available from our cohort of solid
tumour patients, we found high circulating levels of IL-7 in
lymphodepleted patients with other tumours and with sys-
temic vasculitis (Fig. 4), which is in keeping with the litera-
ture. In contrast, we found that basal serum IL-7 levels were
reduced in a range of RA patients, irrespective of inflamma-
tion or medication (Fig. 1b). Furthermore, there was no IL-
7 rise following lymphodepletion (Fig. 4). RA and control
PBMCs responded equivalently to IL-7 stimulation in vitro,
suggesting no defect in IL-7 receptor expression or signal-
ling (Fig. 1d).
Circulating IL-7 levels may also reflect the availability of
specific binding sites on T-cells [6], but our two patient
groups were similarly lymphopenic, making this explanation
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produce IL-7 [52]. Although we were unable to examine
these cells directly, our data do not suggest compensatory
production from that source. Therefore, although we can-
not definitively exclude alternative explanations for reduced
IL-7 levels, low levels in lymphopenic RA patients (Fig. 4)
and the variable ability to recover IL-7 in remission (Fig. 5)
strongly implicate an underlying defect in IL-7 regulation,
also highlighted by the bone marrow derived stromal cul-
ture (Fig. 1). IL-7 expression is upregulated or downregu-
lated by different cytokines in different tissues
(transforming growth factor-β, interferon-γ, TNF-α, IL-1 and
IL-2, among others) and further work is necessary to
uncover the mechanisms that control circulating levels of
IL-7.
CD8+ lymphopenia is also associated with raised circulat-
ing IL-7 levels [53] but this correlation is less strong. This
suggests that factors other than IL-7 can effectively drive
CD8+ T-cell expansion, and it is notable that transient
expansion of CD8+ memory T-cells did occur in RA
patients. Our experience and that of others suggests that
such expansions may be driven by intercurrent infections
(Isaacs JD, unpublished observations) [54]. This may also
underlie the CD8+ T-cell over-compensation observed in
cancer patients (Fig. 2).
The RA thymus was clearly capable of producing new T-
cells. This was evident not only when comparing naïve T-
cell reconstitution in RA and cancer cohorts (Fig. 2) but
also when TREC-containing cells were examined (Fig. 3).
There is a complex relationship between thymic activity, T-
cell proliferation and death, and TREC measurements
[24,42,43,55]. Just after lymphocytotoxic therapy, how-
ever, TREC levels and T-cell counts are low and their sub-
sequent accumulation must therefore reflect thymic output.
TRECs achieved similar peak levels in both RA and cancer
patients, suggesting an equivalent thymic capacity for T-
cell production in these two groups. In cancer patients,
however, TREC levels peaked early, as compared with a
slow rise in RA patients. An association between higher lev-
els of IL-7 and thymic capacity to produce new T-cells was
predictable, based on the direct stimulatory effect of IL-7
on thymic activity at many stages in T-cell progenitor devel-
opment [6,11,56-60] High levels of IL-7, as detected in
lymphopenic control patients, could therefore result in a
burst of thymic activity. In contrast, it is not immediately
obvious what other factor(s) could determine the delayed
rise in thymic activity in RA patients. Other growth factors
are also able to stimulate the thymus [61], but another plau-
sible mechanism is the removal of inhibition. Several of the
cytokines that are abundant in RA, such as IL-6, oncostatin
M and leukaemia inhibitory factor, suppress thymic function
[37]. Levels of TNF-α, IL-6 and oncostatin M fell after high-
dose chemotherapy in RA patients (data not shown) as the
disease entered remission, and this may have resulted in a
corresponding slow increase in thymic activity.
Our data have pathogenic and therapeutic implications.
First, they provide further support for a stromal cell function
defect in RA. Previous studies of bone marrow progenitor
cell reserve and stromal function in RA patients were more
consistent with a defect secondary to TNF-α associated
toxicity [34]. In those studies, progenitor cell reserve was
reduced, and RA stroma was unable to support haemat-
opoiesis from healthy CD34+ progenitors. Both abnormali-
ties correlated with TNF-α levels in bone marrow culture
supernatants and significantly improved after in vivo TNF-α
blockade. Those data therefore support a scenario in which
the RA marrow was suppressed by chronic exposure to
TNF-α and potentially other proinflammatory cytokines.
However, our data relating both to circulating IL-7 and to
bone marrow production demonstrate independence from
the inflammatory process (Fig. 1) at least in some patients,
and are consistent with a primary abnormality.
Therefore, supplementation with recombinant IL-7 may be
necessary to improve lymphocyte reconstitution in lympho-
penic RA patients, with the caveat that this cytokine is also
a co-stimulatory factor for T-cells. It may therefore encour-
age the expansion of autoreactive T-cells with a worsening
of disease. For example, IL-7 has been associated with
preferential expansion [62] and activation [63] of autoreac-
tive T-cells in multiple sclerosis. Additionally, IL-7 has been
associated with lymphoproliferative disorders [64-66] to
which RA patients are already predisposed. Furthermore,
our data do not exclude additional contributions to limited
T-cell expansion, and proliferative exhaustion is a factor that
may not be amenable to therapeutic intervention. It is there-
fore possible that terminally differentiated memory T-cells,
resulting from chronic immune activation in RA, cannot pro-
liferate in response to lymphopenia. This does not explain
the lack of proliferation of naïve T-cells from RA patients,
however (Figs 2 and 3).
Conclusion
In conclusion, although our data are necessarily an aver-
aged view of events that occur after lymphodepletion, we
have made a number of observations relevant to poor T-cell
reconstitution in lymphopenic RA patients. Importantly, the
RA thymus is capable of producing naïve T-cells but its
function is compromised by an IL-7 deficiency. The latter
also severely limits the peripheral expansion of both naïve
and memory T-cells. Our data suggest potential
approaches to correct lymphocyte reconstitution defects in
RA patients receiving lymphocytotoxic therapies and pro-
vide further insights into the disease process itself.
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